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Background
The purpose of the study was to determine the influence of an HIV infection with tuberculosis or chronic viral hepatitis on
efficiency and safety during 48 weeks of HAART.
Methods
HAART was received by 327 naı ¨ve HIV patients (pts). Clinical symptoms of an HIV infection had 273 pts (83.5%). The 1st group -
59 HIV pts with tuberculosis, the 2nd group - 217 HIV pts with chronic viral hepatitis, the 3rd group - 51 HIV-monoinfected pts.
All pts were treated with 2 NRTIEFV/PI. Evaluation of HAART efficacy based on the change of amount CD4 cells and RNA HIV
level after 24 and 48 weeks therapy. Safety of HAART was evaluated on the frequency of adverse events and the change of
laboratory abnormalities.
Results
After 24 weeks 6172% of patients had undetectable RNA HIV level. CD4 cells increased in all groups.The percentage of pts with
low CD4 cells (B200 cells/mm
3) decreased from 4055% to 2630%. After 48 weeks HAART CD4 cells increased by 90127
cells/mm
3 (vs baseline) in all pts, however 17.426.7% pts saved low CD4 cells. Undetectable RNA HIV level registered in 75.6%
pts with tuberculosis and 87.588.8% other pts. The proportion of pts who had adverse events was more among 1st and 2nd
groups as compared as HIV-monoinfected pts (3335% and 19%, p B0.05) after 24 weeks of therapy. After 48 weeks HAART the
frequency of adverse events and laboratory abnormalities decreased to 2028% in 1st and 2nd groups and to 2% in 3rd group.
The most frequent we observed CNS disorders (grade 1) due to EFV and gastrointestinal symptoms due to PI or Combivir (CBV).
In pts with accompanying diseases the frequent increase of ALT level was observed in 3040%, in HIV-monoinfected pts - 4
10%. The frequency of interruption HAART was greatest among patients with tuberculosis - 14.3% (vs 5% and 5.8% in patients
with hepatitis and monoinfected patients). In general, the interrupt has been associated with the combination of side effects of
antiretroviral and antituberculosis drugs.
Conclusions
Availability of chronic liver disease or tuberculosis almost have no influence on the HAART efficacy. However, essential increase
the frequency of adverse events HAART that leads to change HAART regimen or interruption it.
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